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Abstract
Background: Acute hepatic porphyria (AHP) consists of three rare metabolic disorders. We investigated the risk of
long-term sick leave, disability pension, and premature death in individuals with AHP compared to the general
population.
Methods: In a nationwide cohort study from 1992 to 2017, records of 333 persons (total person-years = 6728) with
a confirmed AHP diagnosis were linked to several national compulsory registries (reference population = 5,819,937).
We conducted survival analyses to assess additional risk.
Results: Persons with AHP had higher risks of accessing long-term sick leave (adjusted hazard ratio (aHR): 1.5, 95%
confidence interval (CI): 1.3, 1.7) and disability pension (aHR: 1.9, CI: 1.5, 2.4). The risk was highest in persons who
had been hospitalised for acute attacks, while no additional risk was observed in asymptomatic AHP gene mutation
carriers. The median age when accessing disability pension was 45 years, 21 years younger than the general
population. AHP was associated with increased risk of mortality due to hepatocellular carcinoma (adjusted mortality
rate ratio (aMRR): 84.4, CI: 37.8, 188.2), but no overall increased risk of premature death was observed.
Conclusions: Persons with symptomatic AHP were at increased risk of accessing long-term sick leave and disability
pension but not of premature death.
Keywords: Acute hepatic porphyria, Acute intermittent porphyria, Variegate porphyria, Hereditary coproporphyria,
Long-term sick leave, Disability pension, Morbidity, Premature death, Mortality
Background
Autosomal dominant acute hepatic porphyria (AHP) re-
fers to three rare metabolic disorders that affect the bio-
synthesis of haem, namely acute intermittent porphyria
(AIP), variegate porphyria (VP) and hereditary copropor-
phyria (HCP). All can present clinically in the form of
acute neurovisceral attacks characterized by neuropathic
pain, mostly abdominal, and may be accompanied by mus-
cular pain, nausea, vomiting, constipation, general malaise,
fatigue, psychiatric and neurological symptoms [1]. Acute
attacks typically do not occur until adulthood and are
more common in women [1]. However, the clinical pres-
entation is highly variable. If left untreated, attacks can re-
sult in seizures, paralysis, and, in very rare situations,
death [2]. VP and HCP may present with solely cutaneous
lesions or both acute and cutaneous symptoms.
AHP is characterized by the accumulation of porphy-
rin precursors 5-aminolevulinic acide (ALA) and por-
phobilinogen (PBG), and in VP and HCP, porphyrins
[3]. ALA and PBG concentrations are increased during
acute attacks [4]. Symptomatic AIP has an estimated
prevalence in Norway of seven in 100,000 persons [5]. In
European countries, the prevalence of VP and HCP are
estimated at one in 30,000 and less than one in 50,000,
respectively [6]. However, clinical penetrance is incom-
plete, with many genetically predisposed never having
symptoms. The overall prevalence of clinically relevant
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AIP gene mutations may be as high as ~ 6/1000 among
caucasians [7].
Persons with symptomatic AHP report low health-
related quality of life [8–10] and high access rates to long-
term sick leave and disability pension [1, 11]. Persons with
more severe recurrent acute attacks further report debili-
tating chronic symptoms between attacks, such as chronic
pain, fatigue and aspects of neuropathy [10–13], as well as
high levels of unemployment [14]. However, it is difficult
to determine if such outcomes were increased compared
to the general population or may have been confounded
by, for instance, age, sex, or socio-economic factors. Long-
term complications of AHP, in particular in AIP, include
life-threatening diseases such as kidney failure [15], hyper-
tension [16] and hepatocellular carcinoma (HCC), with
the latter typically presenting in the absence of cirrhosis
and other risk factors [17, 18].
In our study, we aimed to investigate if persons with
AHP were at increased risk of long-term sick leave, dis-
ability pension, and premature death compared to the
general population and if there were any differences in




The Norwegian Porphyria Centre (NAPOS) was estab-
lished in 1999 and maintains an administrative database
system of all persons with either symptomatic or a genetic
predisposition for AHP across Norway. Records include
the AHP diagnosis, date of diagnosis and biochemical and
genetic laboratory test results. Additionally, all such per-
sons are invited to participate in the Norwegian Porphyria
Registry, a national medical quality registry, which was
established in 2002 and is administered by NAPOS [19].
Data for the registry are mostly derived from patient-
reported questionnaires supplemented with laboratory test
results. Participants completed questionnaires two years
following the initial submission, and thereafter, every four
years. The registry is based on patient consent with an
overall participation rate of 71% and an average response
rate to follow-up patient-reported questionnaires of 73%.
Porphyria diagnosis is confirmed either by biochemical
testing and/or DNA analysis, conducted by the Depart-
ment of Medical Biochemistry and Pharmacology and
Centre for Medical Genetics and Molecular Medicine,
Haukeland University Hospital.
The National Registry contains demographic infor-
mation of all Norwegian residents since 1876 and is
administered by the Norwegian Tax Administration
[20]. The National Education Database maintains
individual-based education statistics for all residents
of Norway from primary to tertiary level and is ad-
ministered by Statistics Norway.
The Norwegian Labour and Welfare Administration
has maintained records regarding disbursements of vari-
ous benefits, including long-term sick leave benefit and
disability pension, since 1992 [21]. To qualify for disabil-
ity pension, a person has to be aged 18 years or older
and have a permanently reduced earning capacity by
50% or more due to illness or injury. In Norway, the first
16 calendar days of a sick leave episode are compensated
by the employer. Therefore, data for sick leave episodes
that lasted less than 17 days were not available.
Medical doctors complete a death certificate for all deaths,
which is recorded in the Cause of Death Registry of Norway.
The registry’s degree of coverage is higher than 98% [22].
Using the unique national identification number
assigned to each Norwegian at birth (or immigration),
precise person-level record linkage was performed be-
tween the data-sources.
Study design and study population
We conducted a population based, nationwide, cohort
study using registry data. All Norwegian residents regis-
tered in the National Registry, alive at the study start in
January 1992 or born during 1992–1999, were included
in our initial cohort. The reference population com-
prised of 5,819,937 adults in the initial cohort. Of the
428 persons in Norway with a confirmed diagnosis of
symptomatic AHP or a predictively tested asymptomatic
AHP gene mutation carrier, hereon referred to as
asymptomatic AHP gene mutation carriers, 333 persons
participated in the current study (participation rate = 78%)
(AIP = 292; VP = 32; HCP = 9). They consisted of 292 par-
ticipants from the consent based Norwegian Porphyria
Registry, 19 additional persons from the NAPOS adminis-
trative database system who were invited and gave written
consent to participate in the current study, and 22 persons
from the NAPOS administrative database system who
were deceased at the time of planning the study. The
study period differed according to the availability of the
outcome datasets. Additionally, when investigating long-
term sick leave and disability pension, persons who had
received a disability pension before the study start in Janu-
ary 1992 or who were 67 years of age or older were ex-
cluded. Eligibility criteria and Cohort sizes according to
the three outcomes are displayed in Fig. 1.
We classified persons with AHP into four sub-groups:
1) ‘Hospitalised AHP’, persons who reported having
been hospitalised at least once due to an acute attack’; 2)
‘Non-hospitalised AHP’, persons who reported having
had symptoms of porphyria but never having been expli-
citly hospitalised for an acute attack; 3) ‘Asymptomatic
AHP gene mutation carriers’, persons who reported
never having had symptoms of porphyria; and 4) ‘Un-
classified’, persons with a confirmed AHP diagnosis but
who had not participated in the Norwegian Porphyria
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Registry and therefore had not answered clinically rele-
vant questions.
Selected disease diagnoses and codes for the three out-
come measures are listed in Table 1.
Statistical analysis
Stata/SE Version 15 for Windows was used for all statis-
tical analyses (Software: Release 15, College Station, TX,
USA). We calculated annual incidence rates by dividing
the number of new cases by 100 person-years. We esti-
mated the hazard ratio (HR) and corresponding 95%
confidence intervals (CIs) to assess the risk of accessing
long-term sick leave, disability pension or premature
death in persons with AHP compared to the general
population, by Cox proportional hazard regression
models. Age on the study (months, years) was the time-
scale for the analyses. Porphyria diagnosis (0 = reference
population, 1 = AHP diagnosis) or AHP sub-groups (0 =
reference population, 1 = hospitalised AHP, 2 = non-hos-
pitalised AHP, 3 = asymptomatic, 4 = unclassified) were
entered as exposure variables. The entry time was the
start of the study, or, if younger than 18 years at the study
start, the month and year of the participant’s respective
18th birthday. The exit time was the month and year of
the outcome of interest, death, or the end of the study,
whichever came first. Additionally, persons exited the
study at the retirement age of 67 years when assessing sick
leave and disability pension. When assessing sick leave
benefits, we censored for the date of disability leave. The
Cox regression analyses were stratified by birth cohorts of
20 years, to adjust for calendar effects. We performed
crude analyses, adjusting for age as the time-scale. Further,
Fig. 1 Overview of eligibility criteria and study sample
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we ran models adjusting for sex, and the level of educa-
tional attainment (no education, primary and middle
school education (1 to 10 years), intermediate education
(11, 12, 13) tertiary education (14 years or more), and un-
specified). We produced non-parametric hazard estimate
curves with 95% CIs to visually display risk. Tests of interac-
tions between AHP diagnosis and sex were conducted by in-
cluding a product term in each model. We also investigated
if the highest ever recorded concentration of urinary PBG, or
ALA (ALA/PBG by Column Test, Bio-Rad Diagnostics) pre-
dicted the risk of accessing disability pension in separate Cox
proportional hazard models. The proportionality assumption
of the Cox models was assessed by inspecting Kaplan-Meier
curves and the log(−log (survival)) versus log (time) graphs
for fixed covariates, including time-dependent covariates in
the model for all covariates, and tests of the non-zero slope.
No violations were detected.
To assess differences in diagnostic reasons for long-
term sick leave and disability pension between persons
with AHP and the general population, we conducted
Poisson regression analyses with robust standard errors
to estimate the incident rate ratios (IRR) and CIs, offset
Table 1 Diagnostic codes investigated
Long-term sick leave diagnoses ICPC-2 code
General and unspecified A01-A99
Weakness/ tiredness general A04
Abdominal pain D01-D02, D06
Cardiovascular K01-K99
High blood pressure/hypertensive disorder K85, K86, K87
Ischemic heart disease K76
Muscle/joint – pain/symptoms L18, L19, L20
Neurological N01-N99
Psychological P01-P99
Acute stress reaction P02
Feeling depressed P03
Depressive disorder P76
Endocrine/ metabolism/ nutritional disorder, other T99
Urological symptoms and diseases U01-U99
Disability pension diagnoses ICD-10 code
Neoplasms C00–96, D45–47
Disorders of porphyrin and bilirubin metabolism E80
Mental and behavioral disorders F00-F99
Epilepsy G40
Diseases of the circulatory system I00-I99
Hypertension I10-I15
Ischemic heart disease I20-I25
Diseases of the musculoskeletal system and connective tissue M00-M99
Renal failure N17-N19
Causes of death diagnosis (underlying and contributing) ICD-10 code
Malignant neoplasms C00–96, D45–47
Hepatocellular carcinoma C22.0
Renal carcinoma C64
Type I diabetes E10
Hypertension I10-I11
Ischemic heart disease I20-I25
Renal failure N17-N19
Abbreviations: ICPC-2 International Classification of Primary Care – 2nd edition; ICD-10 International Classification of Diseases (ICD) – 10th revision
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for months on study (month and year of exit minus
month and year of entry).
We performed all analyses in a traditional cohort design,
using the reference population as controls. Additionally,
given the differences in age between our groups, we per-
formed matched case-control analyses of the primary out-
comes. The matched analysis used ten controls to every
case, randomly selected from the population and
frequency-matched on sex, age at study start, and educa-
tional attainment.
In a sensitivity analysis for mortality, 96 non-participants
with an AHP diagnosis, known to be alive by the study end
in 2017, were included in crude analyses.
Ethical approval
The study was approved by the Regional Committees for
Medical and Health Research Ethics, Norway (reference
number: 2012/753).
Results
Participants with non-hospitalised and unclassified AHP
were generally older at the start of the study compared
to the other groups. High proportions of hospitalised
and non-hospitalised AHP subjects were female. The un-
classified subjects tended to have lower educational at-
tainment (Table 2).
Long-term sick leave
Overall, 70% of persons with AHP accessed long-term sick
leave throughout the study period compared to 52% of the
general population, constituting an annual incidence of
9.5% and an HR of 1.5 (95% CI: 1.3, 1.7) (Figs. 1 & 2). The
risk was highest in persons with a history of a hospitalised
acute attack (HR = 2.1, 95% CI: 1.5, 3.0), while not elevated
in asymptomatic AHP gene mutation carriers (HR = 1.0,
95% CI: 0.8, 1.4) (Figs. 2 & 3). Persons with AHP were, on
average, 5 years younger at the time of their first long-
term sick leave episode than the reference population.
































Sex – female 29 69.1 63 60.6 48 47.2 25 54.4 2,427,746 48.4
Age in years (study start) 29.0 (24.9, 33.0) 34.7 (32.2, 37.2) 27.0 (24.6, 29.4) 32.8 (28.7, 36.9) 29.0 (29.0, 29.0)
Education attainment
Unspecified 0 0.0 0 0.0 0 0.0 0 0.0 636,494 12.7
Primary/middle edu (1–10 yrs) 8 19.1 22 21.2 20 19.8 17 37.0 1,113,270 22.2
Intermediate edu (11–13 yrs) 18 42.9 42 40.4 44 43.6 19 41.3 1,827,443 36.4
Tertiary edu (14+ yrs) 16 38.1 40 38.5 37 36.6 10 21.7 1,443,956 28.8
Biochemical characteristics
PBG 24.5 (14.4, 34.5) 11.8 (8.9, 14.7) 4.1 (2.6, 5.5) 7.8 (3.9, 11.7)
ALA 24.5 (11.3, 37.7) 10.9 (8.6, 13.3) 4.9 (4.0, 5.9) 6.8 (4.0, 9.9)
PBG > 4*upper reference limit 33 78.6 68 65.4 24 23.8 15 32.6
PBG > 10*upper reference limit 26 61.9 39 37.5 18 17.8 13 28.3
Smoking
Never / have quit 24 57.1 66 63.5 74 73.3
Occasionally / daily 16 38.1 35 33.7 20 19.8
Not specified 2 4.8 3 2.9 7 6.9
Drinks alcohol > 3 / week
Yes 1 2.4 1 1.0 2 2.0
No 26 61.9 77 74.0 61 60.4
Not specified 15 35.7 26 25.0 38 37.6
Body mass index (BMI) 23.7 (22.5, 24.9) 25.7 (24.8, 26.6) 23.4 (22.5, 24.4)
Note: AHP acute hepatic porphyria; CI confidence intervals; PBG porphobilinogen; ALA: 5-aminolevulinic acid
Lifestyle factors are based on self-reported questionnaires sent to the Norwegian Porphyria Registry. Biochemical characteristics are based on the highest ever
recorded value, recorded mostly outside of an acute attack. PBG upper reference limit > 0.8 umol/mmol creatinine; ALA upper reference limit > 4.6
umol/mmol creatinine
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The main diagnostic reason for long-term sick leave in
patients with AHP was ‘endocrine/metabolism/nutri-
tional disorder’ (n = 52 patients), which includes an AHP
diagnosis (Fig. 4). Psychological symptoms/disorders
were also common reasons for long-term sick leave both
in AHP and the general population (Fig. 4). Compared
to the general population, individuals with an AHP diag-
nosis had an increased risk of a long-term sick leave epi-
sode due to high blood pressure, ischemic heart disease,
endocrine/metabolism/nutritional disorder, and a uro-
logical symptom/disorder (Fig. 4).
Disability pension
Having an AHP diagnosis resulted in a 1.9-fold (95%CI: 1.5,
2.4) increased risk of accessing disability pension compared to
the general population (Figs. 2 & 3). The risk was highest in
persons with hospitalised AHP (HR=4.0, 95%CI: 2.6, 6.3),
who were, on average, 21 years younger than the general
population when accessing disability pension (Figs. 2 & 3).
No trend between highest ever recorded urinary PBG
(p = .246) and ALA (p = .327) concentrations and risk of DP
was detected in persons with AHP. The risk of accessing dis-
ability pension in AHP did not depend on sex (p-value for
interaction= .919). Of those on a disability pension with an
AHP diagnosis, 70 persons had AIP (27% of AIP cases), 8 VP
(31% of VP cases) and 4 HCP (44% of HCP cases).
The most common diagnostic reason persons with
AHP were on a disability pension was because of their
AHP (ICD-10: E80.2), either as a primary diagnosis (n =
16) or secondary diagnosis (n = 9). Of the 16 individuals
who received a disability pension because of their AHP,
six had hospitalised AHP, nine had non-hospitalised
AHP, and one was unclassified. Other diagnostic reasons
for accessing disability pension included mental and be-
havioral disorders (F00-F99), n = 10; diseases of the
circulatory system (I00-I99), n = 10; and diseases of the
musculoskeletal system and connective tissue (M00-
M99), n = 10. However, the risk was comparable to that
of the general population, except for diseases of the cir-
culatory system (aIRR = 3.8, 95% CI: 2.0, 7.1).
Mortality
Persons with AHP had a 1.3-fold (95% CI: 1.0, 1.8)
increased risk of premature death compared to the general
population. In the sub-groups, risk was only increased in
unclassified subjects (aHR = 3.2, 95% CI: 2.1, 4.4), but not
in hospitalised AHP subjects (aHR = 1.0, 95% CI: 0.5, 2.5),
non-hospitalised AHP subjects (aHR = 1.0, 95% CI: 0.6,
1.6), or asymptomatic AHP gene mutation carriers (aHR =
0.7, 95% CI: 0.3, 1.4). In the sensitivity analysis in which
95 non-participants with a known AHP diagnosis (who
were known to be alive by the study end in 2017) were
Fig. 2 Risk of long-term sick leave (17 days or more) at least once over a lifetime and disability pension in persons with acute hepatic porphyria
and the reference population aged 18 to 67 years. Note: IQR: interquartile range (25th, 75th percentiles); AHP: acute hepatic porphyria;
CI: Confidence intervals. The X-scale is logarithmic. Adjusted analysis: Adjusted for age in years (timescale), sex and educational attainment
and stratified by birth cohorts.
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included in crude analysis, no increased risk of premature
death was observed (IRR = 0.8, 95% CI: 0.6, 1.0) (Fig. 5).
There was no observed difference in median age at death
between the total population and persons with AHP or
AHP sub-groups.
Nineteen deaths were due to malignancies, six spe-
cifically due to HCC carcinoma (ICD-10: C22.0), and
five due to ischemic heart disease (ICD-10: I20–25).
Compared to the reference population, an increased
cause-specific risk of death was observed only for
HCC (adjusted mortality rate ratio (aMRR) = 84.4,
95% CI: 37.8, 188.2). In the sensitivity analysis, the
aMRR decreased to 58.9 (95% CI: 26.5, 130.5). Other
causes of death of interest, but with a count less
than three, included: renal carcinoma (C64): n = 2;
porphyria (E80.2), n = 2; and renal failure (N17–19),
n = 2. There was one additional count of HCC, three
counts of hypertensive disorder (I10, I11) and five
additional cases of renal failure (N17–19) listed as
contributing, but not the main underlying cause of
death.
Matched analysis
The results from the matched analysis were essentially
identical to the analysis which used the entire reference
population (Additional file 1: Table S1).
Discussion
AHP is a common term for three porphyria diseases
which have highly variable natural histories and clinical
presentation in different patients. Some AHP gene muta-
tion carriers remain asymptomatic throughout their
lives, some have one to two attacks during their lifetime
while others are severely affected, having recurrent acute
attacks requiring frequent hospitalizations and low qual-
ity of life. Patients with VP and HCP may have symp-
tomatic disease only in the form of skin symptoms. AHP
patients with recurrent acute attacks also report chronic
symptoms outside of attacks, resulting in increased mor-
bidity. The diseases are in addition associated with sev-
eral long-term complications that may increase risk of a
premature death. In a population based cohort study, we
found that having a symptomatic AHP diagnosis was
Fig. 3 Kaplan-Meier curve for cumulative failure probability estimates of first long-term sick leave event and disability pension from 18 to 67 years of
age between persons with acute hepatic porphyria (red line, panel a) and sub groups (red line=hospitalised, green line=non-hospitalised, yellow line=
asymptomatic, purple line=unclassified, panel b) and the reference population (blue lines, panel a and b). Note: AHP: acute hepatic porphyria; CI:
confidence intervals; 95% confidence intervals displayed on panel A only; 95% confidence intervals in panel A of the reference are too small to detect
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associated with increased risks of accessing long-term
sick leave and disability pension. The main diagnostic
reason for this additional risk was the AHP diagnosis
itself, not other comorbidites. HCC was the only
specific underlying cause of death more common in
AHP than in the general population but, we found no
evidence of an overall increased risk of a premature
death.
In a population-based study of 356 persons with AIP
in Northern Sweden, Bylesjo et al. [1] found 20% of the
subjects with symptomatic AIP reported accessing long-
term sick leave or disability pension at a mean age of 45
Fig. 4 Diagnostic reasons for a long-term sick leave episode between persons with AHP acute hepatic porphyria and sub-groups and the
reference population (aged 18 to 67 years). Note: IRR = Incident rate ratios; CI=Confidence intervals; dis = disorder. The X-scale is logarithmic.
Adjusted analysis: Adjusted for age in years, sex and educational attainment and stratified by birth cohorts.
Fig. 5 Kaplan-Meier curve for cumulative mortality estimates from 18 to 67 years of age between persons with AHP (red line, panel a) and sub
groups (red line=hospitalised, green line=non-hospitalised, yellow line=asymptomatic, panel b) and the reference population (blue lines). Note:
AHP: acute hepatic porphyria; CI: confidence intervals; 95% CIs displayed on panel A only; 95% CIs in panel A of the reference are too small to
detect. Excludes persons with unclassified AHP
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years of age. We found 79% of those who self-reported
being hospitalised for an acute attack accessed long-
term sick leave and 46% accessed disability leave. Des-
pite similarities between Norwegian and Swedish social
benefit systems, it remains difficult to directly compare
the results given differences in policies and registration
practices [23], as well as different criteria for the defini-
tions of symptomatic AHP and long-term sick leave be-
tween the two studies. In our study, the median age of
46 years for accessing disability pension was substantially
younger than the general population (21 years differ-
ence). This finding suggests that symptomatic AHP re-
sults in long-term disability that is associated with a
drastic loss in working years.
In the Norwegian Porphyria Registry, half the par-
ticipants with AHP reported having chronic symp-
toms for more than one month, such as fatigue,
stomach pain, and muscle weakness, which they as-
cribed to their AHP. Such findings are also commonly
reported in many qualitative and cross-sectional stud-
ies in patients who have recurrent acute attacks [10,
12, 13]. However, such studies lack sufficient control
groups. In our registry-based cohort study which
compared persons with AHP to the entire population,
we found many long-term sick leave episodes due to
weakness/tiredness (8%), abdominal pain (3%),
muscle/joint pain (4%), acute stress reaction (11%)
and feeling depressed/depressive disorder (20%). How-
ever, such complaints were also common in the gen-
eral population, and we found no evidence that
persons with AHP had a comparatively increased risk
of long-term sick leave due to these reasons. In our
study, AHP was the most prevalent cause of long-
term sick leave or for accessing disability pension.
We found an 84-fold excess risk of mortality due to
HCC compared to the general population. The risk ratio
was reduced to 54 in a crude hypothetical sensitivity
analysis. We have previously described this risk [18],
which has also been reported in other population based
studies from several other countries [18]. An excess risk
of death due to renal impairment has also been de-
scribed in AHP. Andersson and Lithner [16] found that
renal failure was the cause in 9% of AIP deaths between
1978 and 1990 in Northern Sweden. In line with this, we
found that renal failure was cited as the underlying cause
of death in two persons (4% of deaths) and as a contrib-
uting cause in five persons (9% of deaths) out of 55
deaths in total.
In our study, only two deaths were attributed to
AHP itself, accounting for 8% of 24 deaths in persons
who reported having symptomatic AHP. In a study by
Linet et al. [24] conducted in Sweden (1977 and
1993) and Denmark (1965–1989), 41% of deaths were
due to AIP. It is likely that developments in
diagnosis, treatment, and follow-up have improved
survival for persons with AHP and, therefore, this
drop in mortality due to AHP is expected in our
more recent study.
Linet et al. [24] reported a 1.9-fold overall increased
risk of premature death in AIP patients due to cancer
and ischemic heart disease (excluding AIP as a cause of
death). Initially, we found a 1.3-fold increased risk of
premature death but isolated to the unclassified sub-
group, who were overrepresented by persons included in
our study due to their deceased status. In a sensitivity
analysis crude sensitivity analysis using all known per-
sons with an AHP diagnosis across Norway which did
not support our initial finding, and despite an increased
risk of death due to HCC, we found no evidence of over-
all increased risk of premature death in AHP.
Strengths of the current study included the pro-
spective population-based cohort design with a long
follow-up period. Information regarding the outcomes
was drawn from compulsory national registries and
databases. We used the entire adult Norwegian popu-
lation as our reference group and were able to adjust
for potential confounders like age, sex, and educa-
tional attainment, as a proxy of socioeconomic status.
However, residual confounding cannot be excluded,
though we find it reassuring that results from the
matched case-control and cohort analyses were very
similar.
A limitation of this study was that we were unable
to include all persons with AHP in Norway, as well
as all asymptomatic AHP gene mutation carriers. Par-
ticipation in the study was by consent, and persons
who did not participate may differ to those who did.
However, the consent rate was relatively high at 78%,
negating this bias to an extent. We were also able to
conduct a sensitivity analysis to re-assess our risk ra-
tio estimates for all-cause mortality and death from
HCC. The number of asymptomatic AHP gene muta-
tion carriers is underrepresented in the current study,
as predictive testing for AHP is voluntary and regu-
lated by law in Norway. Another limitation was our
inability to classify some persons with a verified AHP
diagnosis as symptomatic or asymptomatic because
they had not responded to clinical questionnaires. We
were also dependent on self-reported clinical data to
define AHP sub-groups, which may have resulted in
some level of miss-classification. However, biochem-
ical data provided some objective support to these
otherwise self-selected groups, with 79% of the per-
sons reporting having been hospitalised for an acute
attack having at some point had a PBG four times
the laboratory upper reference limit, compared to
24% of asymptomatic AHP gene mutation carriers. Fi-
nally, although long-term sick leave and disability
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pension are available for the entire population and in-
clude both persons consulted as inpatients and outpa-
tients, the data are primarily used for administrative
purposes and, therefore, the diagnostic accuracy of
the data have not been validated. The underlying
diagnostic codes from the Cause of Death Registry of
Norway, on the other hand, has been shown to have
good validity [22].
Conclusion
In summary, we demonstrated in a large population-
based cohort study that persons with symptomatic
AHP were at increased risk of accessing long-term sick
leave and disability pension due to their porphyria.
This risk increased with AHP severity, with persons
hospitalised at least once for an acute attack having
the highest risk and asymptomatic gene mutation car-
riers having no additional risk. Although the risk of
dying from HCC was found to be increased in symp-
tomatic AHP, we found no evidence of overall in-
creased risk of premature death in persons with
symptomatic or asymptomatic AHP.
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